Skip to content

Edwards Cardioband European Post-Market Study, MiBAND

Transcatheter Repair of Mitral Regurgitation With Cardioband System Post Market Study:A European Prospective, Multicenter Study to Assess Transcatheter Mitral Valve Repair With Edwards Cardioband System in Patients With Symptomatic MR

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03600688
Acronym
MiBAND
Enrollment
200
Registered
2018-07-26
Start date
2018-06-06
Completion date
2023-12-31
Last updated
2023-01-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Annuloplasty, Edwards Cardioband, Mitral Insufficiency, Mitral Regurgitation, Mitral Repair, Mitral Valve

Brief summary

To demonstrate reduction of MR with durable performance and im-provements in functional status

Detailed description

MiBAND is a prospective, single arm, European post-market study to assess the safety and efficacy of the Edwards Cardioband system. Patients will be followed up at 30D, 6months, 1, 2 and 3 years.

Interventions

Transcatheter mitral valve repair

Sponsors

Edwards Lifesciences
Lead SponsorINDUSTRY

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

Main Inclusion Criteria: * Age ≥ 18 years; * MR (≥ 2+ by echocardiography); * Patient is eligible to receive the Edwards Cardioband Mitral System Main

Exclusion criteria

* Active bacterial endocarditis * Severe organic lesions with retracted chordae or congenital mal-formations with lack of valvular tissue * Heavily calcified annulus or leaflets * Patients in whom transesophageal echocardiography is contraindicated * Patients who cannot tolerate an anticoagulation/antiplatelet regimen * Patients with known severe reaction to contrast agents that cannot be adequately pre-medicated. * Pre-existing prosthetic heart valve or annuloplasty in the Mitral position * Life expectancy of less than twelve months * Patient is pregnant or lactating

Design outcomes

Primary

MeasureTime frameDescription
Procedure Success at dischargeHospital discharge; approximately 2-8 days post-procedureReduction in Severity of Mitral Regurgitation at discharge

Secondary

MeasureTime frameDescription
Procedure Success30 days, 6months, 1, 2 and 3 yearsReduction in Severity of Mitral Regurgitation
Major Adverse Events Rate30 days, 6months, 1, 2 and 3 yearsRate of Major Adverse Events
Change in Quality Of Life-KCCQ30 days, 6 months, 1, 2 and 3 yearsImprovements in Quality Of Life as assessed by KCCQ
Change in Quality Of Life-EQ-5D-5L30 days, 6 months, 1, 2 and 3 yearsImprovements in Quality Of Life as assessed by EQ-5D-5L

Countries

Germany, Italy, Switzerland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026